DS
ODTX

David Shaw’s Odyssey Therapeutics ODTX Stock Holding History

David Shaw’s Portfolio ODTX Stock Details ODTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$371K Buy
+19,848
New +$348K ﹤0.01% 4323

Other funds holding ODTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
LMC
Lightspeed Management Company Menlo Park, California $2.4B AUM 7.07% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
GCGM
General Catalyst Group Management Cambridge, Massachusetts $189M AUM 10.96% 1-Year Est. Return

David Shaw's ODTX Position: Q2 2026 in Review

David Shaw opened a new position in Odyssey Therapeutics (ODTX) in Q2 2026: 19,848 shares worth $371K. The stake represents ﹤0.01% of the portfolio and ranks #4323 among its holdings.

58 funds tracked by Wall St. Rank hold ODTX as of Q2 2026.

  • David Shaw held 19,848 shares of Odyssey Therapeutics worth $371K as of Q2 2026.
  • Odyssey Therapeutics was a new David Shaw position in Q2 2026.
  • Odyssey Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #4323 holding.
  • 58 funds tracked by Wall St. Rank held Odyssey Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.